Physician profile
Mark S Rasnake
NPI 1962464644
$1,489.97
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $387 · 2021: $185 · 2023: $115 · 2024: $19.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $135.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $315.06 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $239.69 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $141.96 | 2019-2020 | |
| Insmed, INC. | $121.27 | 2019-2021 | |
| Angiodynamics, INC. | $115.22 | 2023 | Angiovac |
| Pfizer INC. | $91.22 | 2019-2020 | |
| Janssen Products, LP | $65.00 | 2021 | |
| Astellas Pharma US INC | $64.74 | 2019 | |
| Alexion Pharmaceuticals, INC. | $42.63 | 2020 | |
| Xeris Pharmaceuticals, INC. | $42.20 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $36.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.93 | 2019-2020 | |
| Amgen INC. | $32.64 | 2019 | |
| Mylan Specialty L.P. | $23.40 | 2020 | |
| Ferring Pharmaceuticals INC. | $19.89 | 2024 | Rebyota |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $17.69 | 2019 | |
| Atricure, INC. | $17.35 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.62 | 2019 | |
| Biosense Webster, INC. | $14.44 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.27 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $11.93 | 2019 | |
| Vifor Pharma, INC. | $11.64 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rasnake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.